Figure 3 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma

Abstract

<p>Synergy of combined vandetanib and everolimus <i>in vitro</i>. <b>A,</b> Cell viability matrix for <i>ACVR1</i><sup>R206H</sup> HSJD-DIPG-007 cells treated with distinct combinations of vandetanib (<i>y</i>-axis) and everolimus (<i>x</i>-axis) ranging from 0 to 20 μmol/L. <b>B,</b> Excess above Bliss matrix for <i>ACVR1</i><sup>R206H</sup> HSJD-DIPG-007 cells treated with distinct combinations of vandetanib (<i>y</i>-axis) and everolimus (<i>x</i>-axis) ranging from 0 to 20 μmol/L. <b>C,</b> Bliss synergy map for <i>ACVR1</i><sup>R206H</sup> HSJD-DIPG-007 cells treated with distinct combinations of vandetanib (<i>y</i>-axis) and everolimus (<i>x</i>-axis) ranging from 0 to 10 μmol/L. Heat maps colored according to the keys provided. <b>D,</b> Cell viability matrix for <i>ACVR1</i><sup>R258G</sup> HSJD-DIPG-018 cells treated with distinct combinations of vandetanib (<i>y</i>-axis) and everolimus (<i>x</i>-axis) ranging from 0 to 20 μmol/L. <b>E,</b> Excess above Bliss matrix for <i>ACVR1</i><sup>R258G</sup> HSJD-DIPG-018 cells treated with distinct combinations of vandetanib (<i>y</i>-axis) and everolimus (<i>x</i>-axis) ranging from 0 to 20 μmol/L. <b>F,</b> Bliss synergy map for <i>ACVR1</i><sup>R258G</sup> HSJD-DIPG-018 cells treated with distinct combinations of vandetanib (<i>y</i>-axis) and everolimus (<i>x</i>-axis) ranging from 0 to 10 μmol/L. Heat maps colored according to the keys provided.</p>

Related Publications